REGENXBIO is a biotechnology company dedicated to advancing gene therapies using its proprietary adeno-associated virus (AAV) platform. The company focuses on developing innovative treatments for serious diseases, particularly in the areas of ophthalmology, neuroscience, and rare genetic disorders. REGENXBIO is committed to improving patient outcomes and enhancing the quality of life for individuals and families affected by these conditions. With core values of Trust, Accountability, Perseverance, and Innovation, REGENXBIO fosters a collaborative and supportive work environment that emphasizes scientific excellence and personal growth. Employees play a vital role in the company’s mission, contributing to groundbreaking therapies that have the potential to transform healthcare. Through a culture of teamwork and shared objectives, REGENXBIO continues to push the boundaries of what is possible in gene therapy.